Toll Free: 1-888-928-9744

Pol Polyprotein - Pipeline Review, H1 2016

Published: Jun, 2016 | Pages: 52 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Pol Polyprotein - Pipeline Review, H1 2016

Summary

Global Markets Direct's, 'Pol Polyprotein - Pipeline Review, H1 2016', provides in depth analysis on Pol Polyprotein targeted pipeline therapeutics. 

The report provides comprehensive information on the Pol Polyprotein, targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Pol Polyprotein targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Pol Polyprotein
- The report reviews Pol Polyprotein targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in Pol Polyprotein targeted therapeutics and enlists all their major and minor projects 
- The report assesses Pol Polyprotein targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news and deals related to Pol Polyprotein targeted therapeutics

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand the targeted therapy areas and indications for Pol Polyprotein
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Pol Polyprotein development landscape 
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
 Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Pol Polyprotein Overview 6 Therapeutics Development 7 Pol Polyprotein - Products under Development by Stage of Development 7 Pol Polyprotein - Products under Development by Therapy Area 8 Pol Polyprotein - Products under Development by Indication 9 Pol Polyprotein - Pipeline Products Glance 10 Late Stage Products 10 Early Stage Products 11 Pol Polyprotein - Products under Development by Companies 12 Pol Polyprotein - Products under Development by Universities/Institutes 14 Pol Polyprotein - Therapeutics Assessment 16 Assessment by Monotherapy/Combination Products 16 Assessment by Route of Administration 17 Assessment by Molecule Type 19 Pol Polyprotein - Companies Involved in Therapeutics Development 21 GeoVax Labs, Inc. 21 Inovio Pharmaceuticals, Inc. 22 Johnson & Johnson 23 Pol Polyprotein - Drug Profiles 24 GOVXB-11 - Drug Profile 24 Product Description 24 Mechanism Of Action 24 R&D Progress 24 GOVXC-11 - Drug Profile 27 Product Description 27 Mechanism Of Action 27 R&D Progress 27 GOVXC-21 - Drug Profile 28 Product Description 28 Mechanism Of Action 28 R&D Progress 28 HIV [serotype Ad26] (tetravalent) vaccine - Drug Profile 29 Product Description 29 Mechanism Of Action 29 R&D Progress 29 HIV-1 (bivalent) vaccine - Drug Profile 30 Product Description 30 Mechanism Of Action 30 R&D Progress 30 HIV-1 vaccine 11 - Drug Profile 31 Product Description 31 Mechanism Of Action 31 R&D Progress 31 HIV-1 vaccine 5 - Drug Profile 32 Product Description 32 Mechanism Of Action 32 R&D Progress 32 PENNVAX-B - Drug Profile 33 Product Description 33 Mechanism Of Action 33 R&D Progress 33 PENNVAX-GP - Drug Profile 36 Product Description 36 Mechanism Of Action 36 R&D Progress 36 Pol Polyprotein - Dormant Projects 38 Pol Polyprotein - Featured News & Press Releases 39 May 18, 2016: GeoVax Observes HIV Vaccine Awareness Day And Prepares for Next Human Clinical Trial of GOVX-B11 39 Apr 14, 2016: GeoVax Awarded $1.4M NIH Grant 40 Mar 07, 2016: Strong Protection Elicited by an Immunodeficiency Virus Vaccine in Non-Human Primates 40 Sep 08, 2015: Inovio Pharmaceuticals Announces First Patient Dosed With Universal HIV Vaccine 41 Apr 14, 2015: GeoVax to Seek Dual Pathway for Advancing Its HIV Preventive Vaccine 42 Apr 09, 2015: GeoVax Provides Details of Presentation at World Vaccine Congress 42 Apr 01, 2015: GeoVax Provides Update on Its HIV Vaccine Program 43 Mar 16, 2015: Inovio Pharmaceuticals and Academic Collaborators Receive $16 Million HIV Grant From National Institute of Allergy and Infectious Diseases 44 Jan 06, 2015: Inovio Pharmaceuticals HIV Immunotherapy Shows Characteristics Considered Vital to Treating HIV 45 Oct 29, 2014: GeoVax Presents HIV Vaccine Clinical Trial Data 46 Jul 30, 2014: GeoVax Awarded Small Business Innovative Research (SBIR) Grant from National Institutes of Health 47 Jan 23, 2014: GeoVax Announces Publication of Phase 2a Clinical Trial in The Journal of Infectious Diseases 47 Jan 13, 2014: GeoVax Announces Preliminary Top-Line Results for Phase 1 Therapeutic Vaccine Trial in HIV-Infected Patients 48 Oct 09, 2013: GeoVax DNA/MVA Vaccine Elicits Sustained Antibody Responses to HIV 49 Jan 10, 2013: GeoVax Announces Enrollment Completion For Phase I/II Clinical Trial For HIV/AIDS Therapeutic Vaccine 50 Appendix 51 Methodology 51 Coverage 51 Secondary Research 51 Primary Research 51 Expert Panel Validation 51 Contact Us 51 Disclaimer 52
List of Tables
Number of Products under Development for, H1 2016 7 Number of Products under Development by Therapy Area, H1 2016 8 Number of Products under Development by Indication, H1 2016 9 Comparative Analysis by Late Stage Development, H1 2016 10 Comparative Analysis by Early Stage Products, H1 2016 11 Number of Products under Development by Companies, H1 2016 12 Products under Development by Companies, H1 2016 13 Number of Products under Investigation by Universities/Institutes, H1 2016 14 Products under Investigation by Universities/Institutes, H1 2016 15 Assessment by Monotherapy/Combination Products, H1 2016 16 Number of Products by Stage and Route of Administration, H1 2016 18 Number of Products by Stage and Molecule Type, H1 2016 20 Pipeline by GeoVax Labs, Inc., H1 2016 21 Pipeline by Inovio Pharmaceuticals, Inc., H1 2016 22 Pipeline by Johnson & Johnson, H1 2016 23 Dormant Projects, H1 2016 38



To request a free sample copy of this report, please complete the form below.

We never share your personal data. Privacy policy
Interested in this report? Get your FREE sample now! Get a Free Sample
Choose License Type
Single User - US $3500
Multi User - US $7000
Hexareeasearch Know

Did you know?

Research Assistance

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Why to buy from us

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Information security

Your personal and confidential information is safe and secure.

verify